<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39319247</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>26</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2398-8835</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Health science reports</Title><ISOAbbreviation>Health Sci Rep</ISOAbbreviation></Journal><ArticleTitle>HIV vaccination: Navigating the path to a transformative breakthrough-A review of current evidence.</ArticleTitle><Pagination><StartPage>e70089</StartPage><MedlinePgn>e70089</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e70089</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1002/hsr2.70089</ELocationID><Abstract><AbstractText Label="BACKGROUND AND AIM" NlmCategory="UNASSIGNED">Human immunodeficiency virus (HIV) remains a significant global health challenge, with approximately 39 million people living with HIV worldwide as of 2022. Despite progress in antiretroviral therapy, achieving the UNAIDS "95-95-95" target to end the HIV epidemic by 2025 faces challenges, particularly in sub-Saharan Africa. The pursuit of an HIV vaccine is crucial, offering durable immunity and the potential to end the epidemic. Challenges in vaccine development include the lack of known immune correlates, suitable animal models, and HIV's high mutation rate. This study aims to explore the current state of HIV vaccine development, focusing on the challenges and innovative approaches being investigated.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">In writing this review, we conducted a search of medical databases such as PubMed, ResearchGate, Web of Science, Google Scholar, and Scopus. The exploration of messenger ribonucleic acid vaccines, which have proven successful in the SARS-CoV-2 pandemic, presents a promising avenue for HIV vaccine development. Understanding HIV-1's ability to infiltrate various bodily compartments, establish reservoirs, and manipulate immune responses is critical. Robust cytotoxic T lymphocytes and broadly neutralizing antibodies are identified as key components, though their production faces challenges. Innovative approaches, including computational learning and advanced drug delivery systems, are being investigated to effectively activate the immune system.</AbstractText><AbstractText Label="RESULTS AND CONCLUSIONS" NlmCategory="UNASSIGNED">Discrepancies between animal models and human responses have hindered the progress of vaccine development. Despite these challenges, ongoing research is focused on overcoming these obstacles through advanced methodologies and technologies. Addressing the challenges in HIV vaccine development is paramount to realizing an effective HIV-1 vaccine and achieving the goal of ending the epidemic. The integration of innovative approaches and a deeper understanding of HIV-1's mechanisms are essential steps toward this transformative breakthrough.</AbstractText><CopyrightInformation>© 2024 The Authors. Health Science Reports published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Scott</LastName><ForeName>Godfred Yawson</ForeName><Initials>GY</Initials><Identifier Source="ORCID">0000-0001-7531-4213</Identifier><AffiliationInfo><Affiliation>Department of Medical Diagnostics Kwame Nkrumah University of Science and Technology Kumasi Ghana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Worku</LastName><ForeName>Dominic</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Infectious Diseases Department Morriston Hospital, Heol Maes Eglwys Morriston United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Public Health Wales Cardiff United Kingdom.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Health Sci Rep</MedlineTA><NlmUniqueID>101728855</NlmUniqueID><ISSNLinking>2398-8835</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">AIDS</Keyword><Keyword MajorTopicYN="N">HIV</Keyword><Keyword MajorTopicYN="N">immune system</Keyword><Keyword MajorTopicYN="N">infections</Keyword><Keyword MajorTopicYN="N">vaccines</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>2</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>25</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>25</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>25</Day><Hour>4</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39319247</ArticleId><ArticleId IdType="pmc">PMC11420300</ArticleId><ArticleId IdType="doi">10.1002/hsr2.70089</ArticleId><ArticleId IdType="pii">HSR270089</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>j0294‐who‐hiv‐epi‐factsheet‐v7.pdf. 2023. Accessed February 13, 2024. https://cdn.who.int/media/docs/default-source/hq-hiv-hepatitis-and-stis-library/j0294-who-hiv-epi-factsheet-v7.pdf
</Citation></Reference><Reference><Citation>Global HIV Programme. 2024. Accessed February 13, 2024. 2024. Accessed February 13, https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/hiv/strategic-information/hiv-data-and-statistics
</Citation></Reference><Reference><Citation>Local Burden of Disease HIV Collaborators . Subnational mapping of HIV incidence and mortality among individuals aged 15–49 years in sub‐Saharan Africa, 2000–18: a modelling study. Lancet HIV. 2021;8(6):e363‐e375.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8187986</ArticleId><ArticleId IdType="pubmed">34087097</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahy MI, Sabin KM, Feizzadeh A, Wanyeki I. Progress towards 2020 global HIV impact and treatment targets. J Int AIDS Soc. 2021;24(suppl 5):e25779.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8454678</ArticleId><ArticleId IdType="pubmed">34546655</ArticleId></ArticleIdList></Reference><Reference><Citation>Frescura L, Godfrey‐Faussett P, Feizzadeh A. A , et al. Achieving the 95 95 95 targets for all: a pathway to ending AIDS. PLoS One. 2022;17(8):e0272405.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9352102</ArticleId><ArticleId IdType="pubmed">35925943</ArticleId></ArticleIdList></Reference><Reference><Citation>Marsh K, Eaton JW, Mahy M, et al. Global, regional and country‐level 90‐90‐90 estimates for 2018: assessing progress towards the 2020 target. AIDS. 2019;33:S213‐S226.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6919229</ArticleId><ArticleId IdType="pubmed">31490781</ArticleId></ArticleIdList></Reference><Reference><Citation>Heath K, Levi J, Hill A. The Joint United Nations Programme on HIV/AIDS 95‐95‐95 targets: worldwide clinical and cost benefits of generic manufacture. AIDS. 2021;35(suppl 2):S197‐S203.</Citation><ArticleIdList><ArticleId IdType="pubmed">34115649</ArticleId></ArticleIdList></Reference><Reference><Citation>Payne D, Wadonda‐Kabondo N, Wang A, et al. Trends in HIV prevalence, incidence, and progress towards the UNAIDS 95‐95‐95 targets in Malawi among individuals aged 15–64 years: population‐based HIV impact assessments, 2015−16 and 2020−21. Lancet HIV. 2023;10(9):e597‐e605.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10542580</ArticleId><ArticleId IdType="pubmed">37586390</ArticleId></ArticleIdList></Reference><Reference><Citation>HIV prevention: from crisis to opportunity—Key findings from the 2023 Global HIV Prevention Coalition scorecards. 2024. Accessed Aug 1, 2024. 2024. Accessed Aug 1, https://www.unaids.org/en/resources/documents/2024/2023-global-hiv-prevention-coalition-scorecards-key-findings
</Citation></Reference><Reference><Citation>Maheu‐Giroux M, Mishra S. Evidence with 95‐95‐95 that ambitious is feasible. Lancet HIV. 2024;11(4):e203‐e204.</Citation><ArticleIdList><ArticleId IdType="pubmed">38467134</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcus JL, Leyden WA, Alexeeff SE, et al. Comparison of overall and comorbidity‐free life expectancy between insured adults with and without HIV infection, 2000–2016. JAMA Network Open. 2020;3(6):e207954.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7296391</ArticleId><ArticleId IdType="pubmed">32539152</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno S, Perno C, Mallon P, et al. Two‐drug vs. three‐drug combinations for HIV‐1: do we have enough data to make the switch? HIV Med. 2019;20(suppl 4):2‐12.</Citation><ArticleIdList><ArticleId IdType="pubmed">30821898</ArticleId></ArticleIdList></Reference><Reference><Citation>
Angus B, Gary B, Funmi A. BHIVA guidelines for the routine investigation and monitoring of adult HIV‐1‐positive individuals (2019 interim update). https://www.bhiva.org/monitoring-guidelines
</Citation></Reference><Reference><Citation>Freiberg MS, So‐Armah K. HIV and cardiovascular disease: we need a mechanism, and we need a plan. J Am Heart Assoc. 2016;5(3):e003411.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4943288</ArticleId><ArticleId IdType="pubmed">27013540</ArticleId></ArticleIdList></Reference><Reference><Citation>Ergin HE, Inga EE, Maung TZ, Javed M, Khan S. HIV, antiretroviral therapy and metabolic alterations: a review. Cureus. 2020;12(5):e8059.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7286589</ArticleId><ArticleId IdType="pubmed">32537277</ArticleId></ArticleIdList></Reference><Reference><Citation>Edwards GG, Miyashita‐Ochoa A, Castillo EG, et al. Long‐acting injectable therapy for people with HIV: looking ahead with lessons from psychiatry and addiction medicine. AIDS Behav. 2023;27(1):10‐24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9443641</ArticleId><ArticleId IdType="pubmed">36063243</ArticleId></ArticleIdList></Reference><Reference><Citation>Whiteley LB, Olsen EM, Haubrick KK, Odoom E, Tarantino N, Brown LK. A review of interventions to enhance HIV medication adherence. Curr HIV/AIDS Rep. 2021;18(5):443‐457.</Citation><ArticleIdList><ArticleId IdType="pubmed">34152554</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Lee E, Park BJ, Bang JH, Lee JY. Adherence to antiretroviral therapy and factors affecting low medication adherence among incident HIV‐infected individuals during 2009–2016: a nationwide study. Sci Rep. 2018;8(1):3133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5816616</ArticleId><ArticleId IdType="pubmed">29453393</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim YS. Long‐acting injectable antiretroviral agents for HIV treatment and prevention. Infect Chemother. 2021;53(4):686‐695.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8731252</ArticleId><ArticleId IdType="pubmed">34979604</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W, Zhao S, Wu Y, et al. Safety and efficacy of long‐acting injectable agents for HIV‐1: systematic review and meta‐analysis. JMIR Public Health Surveill. 2023;9:e46767.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10415942</ArticleId><ArticleId IdType="pubmed">37498645</ArticleId></ArticleIdList></Reference><Reference><Citation>Fonner VA, Ridgeway K, van der Straten A, et al. Safety and efficacy of long‐acting injectable cabotegravir as preexposure prophylaxis to prevent HIV acquisition. AIDS. 2023;37(6):957‐966.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10090368</ArticleId><ArticleId IdType="pubmed">36723489</ArticleId></ArticleIdList></Reference><Reference><Citation>Jolayemi O, Bogart LM, Storholm ED, et al. Perspectives on preparing for long‐acting injectable treatment for HIV among consumer, clinical and nonclinical stakeholders: a qualitative study exploring the anticipated challenges and opportunities for implementation in Los Angeles County. PLoS One. 2022;17(2):e0262926.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8812879</ArticleId><ArticleId IdType="pubmed">35113892</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenwood B. The contribution of vaccination to global health: past, present and future. Philos Trans R Soc, B. 2014;369(1645):20130433.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4024226</ArticleId><ArticleId IdType="pubmed">24821919</ArticleId></ArticleIdList></Reference><Reference><Citation>Barouch DH. Challenges in the development of an HIV‐1 vaccine. Nature. 2008;455(7213):613‐619.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2572109</ArticleId><ArticleId IdType="pubmed">18833271</ArticleId></ArticleIdList></Reference><Reference><Citation>Trougakos IP, Terpos E, Alexopoulos H, et al. Adverse effects of COVID‐19 mRNA vaccines: the spike hypothesis. Trends Mol Med. 2022;28(7):542‐554.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9021367</ArticleId><ArticleId IdType="pubmed">35537987</ArticleId></ArticleIdList></Reference><Reference><Citation>Haynes BF, Wiehe K, Borrow P, et al. Strategies for HIV‐1 vaccines that induce broadly neutralizing antibodies. Nat Rev Immunol. 2023;23(3):142‐158.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9372928</ArticleId><ArticleId IdType="pubmed">35962033</ArticleId></ArticleIdList></Reference><Reference><Citation>de Montigny S, Adamson BJS, Mâsse BR, et al. Projected effectiveness and added value of HIV vaccination campaigns in South Africa: a modeling study. Sci Rep. 2018;8(1):6066.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5904131</ArticleId><ArticleId IdType="pubmed">29666455</ArticleId></ArticleIdList></Reference><Reference><Citation>
Arhel N. Revisiting HIV‐1 uncoating. Retrovirology. 2010;7:96. https://pubmed.ncbi.nlm.nih.gov/21083892/

</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2998454</ArticleId><ArticleId IdType="pubmed">21083892</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell EM, Hope TJ. HIV‐1 capsid: the multifaceted key player in HIV‐1 infection. Nat Rev Microbiol. 2015;13(8):471‐483.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4876022</ArticleId><ArticleId IdType="pubmed">26179359</ArticleId></ArticleIdList></Reference><Reference><Citation>
Deeks SG, Overbaugh J, Phillips A, Buchbinder S. HIV infection. Nat Rev Dis Primer. 2015;1:15035. https://pubmed.ncbi.nlm.nih.gov/27188527/
</Citation><ArticleIdList><ArticleId IdType="pubmed">27188527</ArticleId></ArticleIdList></Reference><Reference><Citation>
Mailler M, Bernacchi S, Marquet R, Paillart J‐C, Vivet‐Boudou V, Smyth RP. The life‐cycle of the HIV‐1 Gag‐RNA complex. Viruses. 2016;8(9):248. https://pubmed.ncbi.nlm.nih.gov/27626439/

</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5035962</ArticleId><ArticleId IdType="pubmed">27626439</ArticleId></ArticleIdList></Reference><Reference><Citation>
Freed EO. HIV‐1 assembly, release and maturation. Nat Rev Microbiol. 2015;13(8):484‐496. https://pubmed.ncbi.nlm.nih.gov/26119571/

</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6936268</ArticleId><ArticleId IdType="pubmed">26119571</ArticleId></ArticleIdList></Reference><Reference><Citation>
Goodsell DS. Illustrations of the HIV life cycle. Curr Top Microbiol Immunol. 2015;389:243‐252. https://pubmed.ncbi.nlm.nih.gov/25716304/

</Citation><ArticleIdList><ArticleId IdType="pubmed">25716304</ArticleId></ArticleIdList></Reference><Reference><Citation>Jasinska AJ, Pandrea I, Apetrei C. CCR5 as a coreceptor for human immunodeficiency virus and simian immunodeficiency viruses: a prototypic love‐hate affair. Front Immunol. 2022;13:835994.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8829453</ArticleId><ArticleId IdType="pubmed">35154162</ArticleId></ArticleIdList></Reference><Reference><Citation>Alkhatib G. The biology of CCR5 and CXCR4. Current Opinion in HIV and AIDS. 2009;4(2):96‐103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2718543</ArticleId><ArticleId IdType="pubmed">19339947</ArticleId></ArticleIdList></Reference><Reference><Citation>HIV Replication Cycle | NIH: National Institute of Allergy and Infectious Diseases. 2018. Accessed November 21, 2023. https://www.niaid.nih.gov/diseases-conditions/hiv-replication-cycle
</Citation></Reference><Reference><Citation>
Negi G, Sharma A, Dey M, Dhanawat G, Parveen N. Membrane attachment and fusion of HIV‐1, influenza A, and SARS‐CoV‐2: resolving the mechanisms with biophysical methods. Biophys Rev. 2022;14(5):1109‐1140. https://pubmed.ncbi.nlm.nih.gov/36249860/

</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9552142</ArticleId><ArticleId IdType="pubmed">36249860</ArticleId></ArticleIdList></Reference><Reference><Citation>
Xiao T, Cai Y, Chen B. HIV‐1 entry and membrane fusion inhibitors. Viruses. 2021;13(5):735. https://pubmed.ncbi.nlm.nih.gov/33922579/

</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8146413</ArticleId><ArticleId IdType="pubmed">33922579</ArticleId></ArticleIdList></Reference><Reference><Citation>Sapp N, Burge N, Cox K, et al. HIV‐1 preintegration complex preferentially integrates the viral DNA into nucleosomes containing trimethylated histone 3‐lysine 36 modification and flanking linker DNA. J Virol. 2022;96(18):e0101122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9517705</ArticleId><ArticleId IdType="pubmed">36094316</ArticleId></ArticleIdList></Reference><Reference><Citation>Rozina A, Anisenko A, Kikhai T, Silkina M, Gottikh M. Complex relationships between HIV‐1 integrase and its cellular partners. Int J Mol Sci. 2022;23(20):12341.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9603942</ArticleId><ArticleId IdType="pubmed">36293197</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielsen M, Pedersen F, Kjems J. Molecular strategies to inhibit HIV‐1 replication. Retrovirology. 2005;2(1):10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC553987</ArticleId><ArticleId IdType="pubmed">15715913</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebina H, Misawa N, Kanemura Y, Koyanagi Y. Harnessing the CRISPR/Cas9 system to disrupt latent HIV‐1 provirus. Sci Rep. 2013;3(1):2510.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3752613</ArticleId><ArticleId IdType="pubmed">23974631</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Ma X, Jing S, Zhang H, Zhang Y. Non‐coding RNAs and retroviruses. Retrovirology. 2018;15(1):20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5807749</ArticleId><ArticleId IdType="pubmed">29426337</ArticleId></ArticleIdList></Reference><Reference><Citation>The HIV Life Cycle | NIH. 2021. Accessed November 23, 2023. 2021. Accessed November 23, 2023. https://hivinfo.nih.gov/understanding-hiv/fact-sheets/hiv-life-cycle
</Citation></Reference><Reference><Citation>Shcherbatova O, Grebennikov D, Sazonov I, Meyerhans A, Bocharov G. Modeling of the HIV‐1 life cycle in productively infected cells to predict novel therapeutic targets. Pathogens. 2020;9(4):255.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7238236</ArticleId><ArticleId IdType="pubmed">32244421</ArticleId></ArticleIdList></Reference><Reference><Citation>Sundquist WI, Krausslich HG. HIV‐1 assembly, budding, and maturation. Cold Spring Harbor Perspect Med. 2012;2(7):a006924.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3385941</ArticleId><ArticleId IdType="pubmed">22762019</ArticleId></ArticleIdList></Reference><Reference><Citation>Klingler J, Anton H, Réal E, et al. How HIV‐1 gag manipulates its host cell proteins: a focus on interactors of the nucleocapsid domain. Viruses. 2020;12(8):888.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7471995</ArticleId><ArticleId IdType="pubmed">32823718</ArticleId></ArticleIdList></Reference><Reference><Citation>Burniston MT, Cimarelli A, Colgan J, Curtis SP, Luban J. Human immunodeficiency virus type 1 gag polyprotein multimerization requires the nucleocapsid domain and RNA and is promoted by the capsid‐dimer interface and the basic region of matrix protein. J Virol. 1999;73(10):8527‐8540.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC112873</ArticleId><ArticleId IdType="pubmed">10482606</ArticleId></ArticleIdList></Reference><Reference><Citation>Hendricks CM, Cordeiro T, Gomes AP, Stevenson M. The interplay of HIV‐1 and macrophages in viral persistence. Front Microbiol. 2021;12:646447.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8058371</ArticleId><ArticleId IdType="pubmed">33897659</ArticleId></ArticleIdList></Reference><Reference><Citation>Delannoy A, Poirier M, Bell B. Cat and mouse: HIV transcription in latency, immune evasion and cure/remission strategies. Viruses. 2019;11(3):269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6466452</ArticleId><ArticleId IdType="pubmed">30889861</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu L, Yu F, Du L, Xu W, Jiang S. Tactics used by HIV‐1 to evade host innate, adaptive, and intrinsic immunities. Chin Med J. 2013;126(12):2374‐2379.</Citation><ArticleIdList><ArticleId IdType="pubmed">23786957</ArticleId></ArticleIdList></Reference><Reference><Citation>Balasubramaniam M, Pandhare J, Dash C. Immune control of HIV. J Life Sci. 2019;1(1):4‐37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6714987</ArticleId><ArticleId IdType="pubmed">31468033</ArticleId></ArticleIdList></Reference><Reference><Citation>Vidya Vijayan KK, Karthigeyan KP, Tripathi SP, Hanna LE. Pathophysiology of CD4+ T‐cell depletion in HIV‐1 and HIV‐2 infections. Front Immunol. 2017;8:580.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5440548</ArticleId><ArticleId IdType="pubmed">28588579</ArticleId></ArticleIdList></Reference><Reference><Citation>
Abu‐Raya B, Kollmann TR, Marchant A, MacGillivray DM. The immune system of HIV‐exposed uninfected infants. Front Immunol. 2016;7:383. https://www.frontiersin.org/articles/10.3389/fimmu.2016.00383

</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2016.00383</ArticleId><ArticleId IdType="pmc">PMC5039172</ArticleId><ArticleId IdType="pubmed">27733852</ArticleId></ArticleIdList></Reference><Reference><Citation>Casper C, Crane H, Menon M, Money D. HIV/AIDS comorbidities: impact on Cancer, noncommunicable diseases, and reproductive health. In: Holmes KK, Bertozzi S, Bloom BR, Jha P, eds. Major Infectious Diseases. 3rd ed. The International Bank for Reconstruction and Development/The World Bank; 2017.</Citation><ArticleIdList><ArticleId IdType="pubmed">30212097</ArticleId></ArticleIdList></Reference><Reference><Citation>Boasso A, Shearer GM, Chougnet C. Immune dysregulation in human immunodeficiency virus infection: know it, fix it, prevent it? J Intern Med. 2009;265(1):78‐96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2903738</ArticleId><ArticleId IdType="pubmed">19093962</ArticleId></ArticleIdList></Reference><Reference><Citation>Okoye AA, Picker LJ. CD4(+) T‐cell depletion in HIV infection: mechanisms of immunological failure. Immunol Rev. 2013;254(1):54‐64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3729334</ArticleId><ArticleId IdType="pubmed">23772614</ArticleId></ArticleIdList></Reference><Reference><Citation>Février M, Dorgham K, Rebollo A. CD4+ T cell depletion in human immunodeficiency virus (HIV) infection: role of apoptosis. Viruses. 2011;3(5):586‐612.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3185763</ArticleId><ArticleId IdType="pubmed">21994747</ArticleId></ArticleIdList></Reference><Reference><Citation>Mawle AC, Mcdougal JS. Immunology of HIV Infection. In: Schochetman G, George JR, eds. AIDS Testing. Springer New York; 1994:32‐51.</Citation></Reference><Reference><Citation>Borrell M, Fernández I, Etcheverrry F, et al. High rates of long‐term progression in HIV‐1‐positive elite controllers. J Int AIDS Soc. 2021;24(2):e25675.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7900439</ArticleId><ArticleId IdType="pubmed">33619912</ArticleId></ArticleIdList></Reference><Reference><Citation>Saag M, Deeks SG. How do HIV elite controllers do what they do? Clin Infect Dis. 2010;51(2):239‐241.</Citation><ArticleIdList><ArticleId IdType="pubmed">20550453</ArticleId></ArticleIdList></Reference><Reference><Citation>Gebara NY, El Kamari V, Rizk N. HIV‐1 elite controllers: an immunovirological review and clinical perspectives. J Virus Erad. 2019;5(3):163‐166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6816117</ArticleId><ArticleId IdType="pubmed">31700663</ArticleId></ArticleIdList></Reference><Reference><Citation>Goulder PJR, Watkins DI. Impact of MHC class I diversity on immune control of immunodeficiency virus replication. Nat Rev Immunol. 2008;8(8):619‐630.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2963026</ArticleId><ArticleId IdType="pubmed">18617886</ArticleId></ArticleIdList></Reference><Reference><Citation>Hewson T, Lone N, Moore M, Howie S. Interactions of HIV‐1 with antigen‐presenting cells. Immunol Cell Biol. 1999;77(4):289‐303.</Citation><ArticleIdList><ArticleId IdType="pubmed">10457195</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanales‐Belasio E, Raimondo M, Suligoi B, Buttò S. HIV virology and pathogenetic mechanisms of infection: a brief overview. Annali dell'Istituto superiore di sanita. 2010;46:5‐14.</Citation><ArticleIdList><ArticleId IdType="pubmed">20348614</ArticleId></ArticleIdList></Reference><Reference><Citation>Koyanagi N, Kawaguchi Y. Evasion of the cell‐mediated immune response by alphaherpesviruses. Viruses. 2020;12(12):1354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7761393</ArticleId><ArticleId IdType="pubmed">33256093</ArticleId></ArticleIdList></Reference><Reference><Citation>Stumptner‐Cuvelette P, Morchoisne S, Dugast M, et al. HIV‐1 Nef impairs MHC class II antigen presentation and surface expression. Proc Natl Acad Sci. 2001;98(21):12144‐12149.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC59782</ArticleId><ArticleId IdType="pubmed">11593029</ArticleId></ArticleIdList></Reference><Reference><Citation>Staudt RP, Alvarado JJ, Emert‐Sedlak LA, et al. Structure, function, and inhibitor targeting of HIV‐1 Nef‐effector kinase complexes. J Biol Chem. 2020;295(44):15158‐15171.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7606690</ArticleId><ArticleId IdType="pubmed">32862141</ArticleId></ArticleIdList></Reference><Reference><Citation>Wonderlich ER, Leonard JA, Collins KL. HIV immune evasion disruption of antigen presentation by the HIV Nef protein. Adv Virus Res. 2011;80:103‐127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3782996</ArticleId><ArticleId IdType="pubmed">21762823</ArticleId></ArticleIdList></Reference><Reference><Citation>Roeth JF, Collins KL. Human immunodeficiency virus type 1 Nef: adapting to intracellular trafficking pathways. Microbiol Mol Biol Rev. 2006;70(2):548‐563.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1489538</ArticleId><ArticleId IdType="pubmed">16760313</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereira EA, daSilva LLP. HIV‐1 nef: taking control of protein trafficking. Traffic. 2016;17(9):976‐996.</Citation><ArticleIdList><ArticleId IdType="pubmed">27161574</ArticleId></ArticleIdList></Reference><Reference><Citation>Buffalo CZ, Iwamoto Y, Hurley JH, Ren X. How HIV nef proteins hijack membrane traffic to promote infection. J Virol. 2019;93(24):e01322‐19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6880166</ArticleId><ArticleId IdType="pubmed">31578291</ArticleId></ArticleIdList></Reference><Reference><Citation>Blagoveshchenskaya AD, Thomas L, Feliciangeli SF, Hung CH, Thomas G. HIV‐1 Nef downregulates MHC‐I by a PACS‐1‐ and PI3K‐regulated ARF6 endocytic pathway. Cell. 2002;111(6):853‐866.</Citation><ArticleIdList><ArticleId IdType="pubmed">12526811</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubé M, Bego MG, Paquay C, Cohen ÉA. Modulation of HIV‐1‐host interaction: role of the Vpu accessory protein. Retrovirology. 2010;7:114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3022690</ArticleId><ArticleId IdType="pubmed">21176220</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan N, Geiger JD. Role of viral protein U (Vpu) in HIV‐1 infection and pathogenesis. Viruses. 2021;13(8):1466.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8402909</ArticleId><ArticleId IdType="pubmed">34452331</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell RS, Katsura C, Skasko MA, et al. Vpu antagonizes BST‐2‐mediated restriction of HIV‐1 release via β‐TrCP and endo‐lysosomal trafficking. PLoS Pathog. 2009;5(5):e1000450.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2679223</ArticleId><ArticleId IdType="pubmed">19478868</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Tortorec A, Willey S, Neil SJD. Antiviral inhibition of enveloped virus release by tetherin/BST‐2: action and counteraction. Viruses. 2011;3(5):520‐540.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3185764</ArticleId><ArticleId IdType="pubmed">21994744</ArticleId></ArticleIdList></Reference><Reference><Citation>Tetherin antagonism by Vpu protects HIV‐infected cells from antibody‐dependent cell‐mediated cytotoxicity ‐ PubMed. 2014. Accessed November 24, 2023. https://pubmed.ncbi.nlm.nih.gov/24733916/
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4035966</ArticleId><ArticleId IdType="pubmed">24733916</ArticleId></ArticleIdList></Reference><Reference><Citation>Lata S, Mishra R, Banerjea AC. Proteasomal degradation machinery: favorite target of HIV‐1 proteins. Front Microbiol. 2018;9:2738.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6262318</ArticleId><ArticleId IdType="pubmed">30524389</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojas VK, Park IW. Role of the ubiquitin proteasome system (UPS) in the HIV‐1 life cycle. Int J Mol Sci. 2019;20(12):2984.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6628307</ArticleId><ArticleId IdType="pubmed">31248071</ArticleId></ArticleIdList></Reference><Reference><Citation>Guha D, Ayyavoo V. Innate immune evasion strategies by human immunodeficiency virus type 1. ISRN AIDS. 2013;2013:1‐10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3767209</ArticleId><ArticleId IdType="pubmed">24052891</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrington M, Alter G. Innate immune control of HIV. Cold Spring Harbor Perspect Med. 2012;2(7):a007070.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3385945</ArticleId><ArticleId IdType="pubmed">22762020</ArticleId></ArticleIdList></Reference><Reference><Citation>Scholz EMB, Kashuba ADM. The lymph node reservoir: physiology, HIV infection, and antiretroviral therapy. Clin Pharm Ther. 2021;109(4):918‐927.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8005487</ArticleId><ArticleId IdType="pubmed">33529355</ArticleId></ArticleIdList></Reference><Reference><Citation>Blankson JN, Persaud D, Siliciano RF. The challenge of viral reservoirs in HIV‐1 infection. Annu Rev Med. 2002;53(1):557‐593.</Citation><ArticleIdList><ArticleId IdType="pubmed">11818490</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Chen J. HIV reservoir: how to measure it? Curr HIV/AIDS Rep. 2023;20(2):29‐41.</Citation><ArticleIdList><ArticleId IdType="pubmed">37004676</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun W, Gao C, Hartana CA, et al. Phenotypic signatures of immune selection in HIV‐1 reservoir cells. Nature. 2023;614(7947):309‐317.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9908552</ArticleId><ArticleId IdType="pubmed">36599977</ArticleId></ArticleIdList></Reference><Reference><Citation>Chun TW, Stuyver L, Mizell SB, et al. Presence of an inducible HIV‐1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci. 1997;94(24):13193‐13197.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24285</ArticleId><ArticleId IdType="pubmed">9371822</ArticleId></ArticleIdList></Reference><Reference><Citation>Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV‐1 in patients on highly active antiretroviral therapy. Science. 1997;278(5341):1295‐1300.</Citation><ArticleIdList><ArticleId IdType="pubmed">9360927</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong JK, Hezareh M, Günthard HF, et al. Recovery of replication‐competent HIV despite prolonged suppression of plasma viremia. Science. 1997;278(5341):1291‐1295.</Citation><ArticleIdList><ArticleId IdType="pubmed">9360926</ArticleId></ArticleIdList></Reference><Reference><Citation>Siliciano JD, Kajdas J, Finzi D, et al. Long‐term follow‐up studies confirm the stability of the latent reservoir for HIV‐1 in resting CD4+ T cells. Nat Med. 2003;9(6):727‐728.</Citation><ArticleIdList><ArticleId IdType="pubmed">12754504</ArticleId></ArticleIdList></Reference><Reference><Citation>Davey RT, Bhat N, Yoder C, et al. HIV‐1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci. 1999;96(26):15109‐15114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24781</ArticleId><ArticleId IdType="pubmed">10611346</ArticleId></ArticleIdList></Reference><Reference><Citation>Chomont N, El‐Far M, Ancuta P, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med. 2009;15(8):893‐900.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2859814</ArticleId><ArticleId IdType="pubmed">19543283</ArticleId></ArticleIdList></Reference><Reference><Citation>Chun TW. HIV‐infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. J Clin Invest. 2005;115(11):3250‐3255.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1265878</ArticleId><ArticleId IdType="pubmed">16276421</ArticleId></ArticleIdList></Reference><Reference><Citation>Fletcher CV, Staskus K, Wietgrefe SW, et al. Persistent HIV‐1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proc Natl Acad Sci. 2014;111(6):2307‐2312.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3926074</ArticleId><ArticleId IdType="pubmed">24469825</ArticleId></ArticleIdList></Reference><Reference><Citation>Cory TJ, Schacker TW, Stevenson M, Fletcher CV. Overcoming pharmacologic sanctuaries. Curr Opin HIV AIDS. 2013;8(3):190‐195.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677586</ArticleId><ArticleId IdType="pubmed">23454865</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimata JT, Rice AP, Wang J. Challenges and strategies for the eradication of the HIV reservoir. Curr Opin Immunol. 2016;42:65‐70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5086301</ArticleId><ArticleId IdType="pubmed">27288651</ArticleId></ArticleIdList></Reference><Reference><Citation>Besson GJ, Lalama CM, Bosch RJ, et al. HIV‐1 DNA decay dynamics in blood during more than a decade of suppressive antiretroviral therapy. Clin Infect Dis. 2014;59(9):1312‐1321.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4200019</ArticleId><ArticleId IdType="pubmed">25073894</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams A, Menon S, Crowe M, et al. Geographic and population distributions of human immunodeficiency virus (HIV)‐1 and HIV‐2 circulating subtypes: a systematic literature review and meta‐analysis (2010–2021). J Infect Dis. 2023;228(11):1583‐1591.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10681860</ArticleId><ArticleId IdType="pubmed">37592824</ArticleId></ArticleIdList></Reference><Reference><Citation>Bbosa N, Kaleebu P, Ssemwanga D. HIV subtype diversity worldwide. Curr Opin HIV AIDS. 2019;14(3):153‐160.</Citation><ArticleIdList><ArticleId IdType="pubmed">30882484</ArticleId></ArticleIdList></Reference><Reference><Citation>Santoro MM, Perno CF. HIV‐1 genetic variability and clinical implications. ISRN Microbiol. 2013;2013:481314.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3703378</ArticleId><ArticleId IdType="pubmed">23844315</ArticleId></ArticleIdList></Reference><Reference><Citation>Götte M, Li X, Wainberg MA. HIV‐1 reverse transcription: a brief overview focused on structure–function relationships among molecules involved in initiation of the reaction. Arch Biochem Biophys. 1999;365(2):199‐210.</Citation><ArticleIdList><ArticleId IdType="pubmed">10328813</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature. 1995;373(6510):117‐122.</Citation><ArticleIdList><ArticleId IdType="pubmed">7529365</ArticleId></ArticleIdList></Reference><Reference><Citation>Domingo E, García‐Crespo C, Lobo‐Vega R, Perales C. Mutation rates, mutation frequencies, and proofreading‐repair activities in RNA virus genetics. Viruses. 2021;13(9):1882.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8473064</ArticleId><ArticleId IdType="pubmed">34578463</ArticleId></ArticleIdList></Reference><Reference><Citation>Prado JG, Parkin NT, Clotet B, Ruiz L, Martinez‐Picado J. HIV type 1 fitness evolution in antiretroviral‐experienced patients with sustained CD4+ T cell counts but persistent virologic failure. Clin Infect Dis. 2005;41(5):729‐737.</Citation><ArticleIdList><ArticleId IdType="pubmed">16080097</ArticleId></ArticleIdList></Reference><Reference><Citation>HIV‐1 Transmission, Replication Fitness and Disease Progression ‐ PMC. 2008. Accessed Aug 1, 2024. 2008. Accessed Aug 1, 2024. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2846839/
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2846839</ArticleId><ArticleId IdType="pubmed">20354593</ArticleId></ArticleIdList></Reference><Reference><Citation>Moutouh L, Corbeil J, Richman DD. Recombination leads to the rapid emergence of HIV‐1 dually resistant mutants under selective drug pressure. Proc Natl Acad Sci. 1996;93(12):6106‐6111.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC39197</ArticleId><ArticleId IdType="pubmed">8650227</ArticleId></ArticleIdList></Reference><Reference><Citation>Chomont N. Silence, escape and survival drive the persistence of HIV. Nature. 2023;614(7947):236‐237.</Citation><ArticleIdList><ArticleId IdType="pubmed">36599993</ArticleId></ArticleIdList></Reference><Reference><Citation>Naveed M, Ali U, Karobari MI, et al. A vaccine construction against COVID‐19‐associated mucormycosis contrived with immunoinformatics‐based scavenging of potential mucoralean epitopes. Vaccines. 2022;10(5):664.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9147184</ArticleId><ArticleId IdType="pubmed">35632420</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, Liang B, Wang W, et al. Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases. Signal Transduct Target Ther. 2023;8(1):149.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10081433</ArticleId><ArticleId IdType="pubmed">37029123</ArticleId></ArticleIdList></Reference><Reference><Citation>Travieso T, Li J, Mahesh S, Mello JDFRE, Blasi M. The use of viral vectors in vaccine development. NPJ Vaccines. 2022;7(1):1‐10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9253346</ArticleId><ArticleId IdType="pubmed">35787629</ArticleId></ArticleIdList></Reference><Reference><Citation>Palgen JL, Feraoun Y, Dzangué‐Tchoupou G, et al. Optimize prime/boost vaccine strategies: trained immunity as a new player in the game. Front Immunol. 2021;12:612747.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7982481</ArticleId><ArticleId IdType="pubmed">33763063</ArticleId></ArticleIdList></Reference><Reference><Citation>He Q, Mao Q, An C, et al. Heterologous prime‐boost: breaking the protective immune response bottleneck of COVID‐19 vaccine candidates. Emerg Microbes Infect. 2021;10(1):629‐637.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8009122</ArticleId><ArticleId IdType="pubmed">33691606</ArticleId></ArticleIdList></Reference><Reference><Citation>Barouch DH, Whitney JB, Moldt B, et al. Therapeutic efficacy of potent neutralizing HIV‐1‐specific monoclonal antibodies in SHIV‐infected rhesus monkeys. Nature. 2013;503(7475):224‐228.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4017780</ArticleId><ArticleId IdType="pubmed">24172905</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar R, Qureshi H, Deshpande S, Bhattacharya J. Broadly neutralizing antibodies in HIV‐1 treatment and prevention. Thera Adv Vacc Immunother. 2018;6(4):61‐68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6187420</ArticleId><ArticleId IdType="pubmed">30345419</ArticleId></ArticleIdList></Reference><Reference><Citation>Stephenson KE, Wagh K, Korber B, Barouch DH. Vaccines and broadly neutralizing antibodies for HIV‐1 prevention. Annu Rev Immunol. 2020;38:673‐703.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7375352</ArticleId><ArticleId IdType="pubmed">32340576</ArticleId></ArticleIdList></Reference><Reference><Citation>Hargrave A, Mustafa AS, Hanif A, Tunio JH, Hanif SNM. Current status of HIV‐1 vaccines. Vaccines. 2021;9(9):1026.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8471857</ArticleId><ArticleId IdType="pubmed">34579263</ArticleId></ArticleIdList></Reference><Reference><Citation>Caskey M, Klein F, Lorenzi JCC, et al. Viraemia suppressed in HIV‐1‐infected humans by broadly neutralizing antibody 3BNC117. Nature. 2015;522(7557):487‐491.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4890714</ArticleId><ArticleId IdType="pubmed">25855300</ArticleId></ArticleIdList></Reference><Reference><Citation>Lynch RM, Boritz E, Coates EE, et al. Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV‐1 infection. Sci Transl Med. 2015;7(319):319ra206.</Citation><ArticleIdList><ArticleId IdType="pubmed">26702094</ArticleId></ArticleIdList></Reference><Reference><Citation>Riddler SA, Zheng L, Durand CM, et al. Randomized clinical trial to assess the impact of the broadly neutralizing HIV‐1 monoclonal antibody VRC01 on HIV‐1 persistence in individuals on effective ART. Open Forum Infect Dis. 2018;5(10):ofy242.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6195652</ArticleId><ArticleId IdType="pubmed">30364428</ArticleId></ArticleIdList></Reference><Reference><Citation>Shao S, Huang WC, Lin C, et al. An engineered biomimetic MPER peptide vaccine induces weakly HIV neutralizing antibodies in mice. Ann Biomed Eng. 2020;48(7):1991‐2001.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7289672</ArticleId><ArticleId IdType="pubmed">31832930</ArticleId></ArticleIdList></Reference><Reference><Citation>
Duarte J. HIV vaccines: gp120 and beyond. Nat Res. 2018. https://www.nature.com/articles/d42859-018-00010-y
</Citation></Reference><Reference><Citation>Tong T, D'Addabbo A, Xu J, et al. Impact of stabilizing mutations on the antigenic profile and glycosylation of membrane‐expressed HIV‐1 envelope glycoprotein. PLoS Pathog. 2023;19(8):e1011452.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10434953</ArticleId><ArticleId IdType="pubmed">37549185</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao M, Peachman K, Kim J, et al. HIV‐1 variable loop 2 and its importance in HIV‐1 infection and vaccine development. Curr HIV Res. 2013;11(5):427‐438.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4086350</ArticleId><ArticleId IdType="pubmed">24191938</ArticleId></ArticleIdList></Reference><Reference><Citation>Brigati C, Giacca M, Noonan DM, Albini A. HIV Tat, its TARgets and the control of viral gene expression. FEMS Microbiol Lett. 2003;220(1):57‐65.</Citation><ArticleIdList><ArticleId IdType="pubmed">12644228</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark E, Nava B, Caputi M. Tat is a multifunctional viral protein that modulates cellular gene expression and functions. Oncotarget. 2017;8(16):27569‐27581.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5432358</ArticleId><ArticleId IdType="pubmed">28187438</ArticleId></ArticleIdList></Reference><Reference><Citation>Marino J, Maubert ME, Mele AR, Spector C, Wigdahl B, Nonnemacher MR. Functional impact of HIV‐1 Tat on cells of the CNS and its role in HAND. Cell Mol Life Sci. 2020;77(24):5079‐5099.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7674201</ArticleId><ArticleId IdType="pubmed">32577796</ArticleId></ArticleIdList></Reference><Reference><Citation>Ensoli B, Moretti S, Borsetti A, et al. New insights into pathogenesis point to HIV‐1 Tat as a key vaccine target. Arch Virol. 2021;166(11):2955‐2974.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8363864</ArticleId><ArticleId IdType="pubmed">34390393</ArticleId></ArticleIdList></Reference><Reference><Citation>Cafaro A, Tripiciano A, Picconi O, et al. Anti‐Tat immunity in HIV‐1 infection: effects of naturally occurring and vaccine‐induced antibodies against tat on the course of the disease. Vaccines. 2019;7(3):99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6789840</ArticleId><ArticleId IdType="pubmed">31454973</ArticleId></ArticleIdList></Reference><Reference><Citation>Letvin NL. Strategies for an HIV vaccine. J Clin Invest. 2002;110(1):15‐27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC151036</ArticleId><ArticleId IdType="pubmed">12093882</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaseke C, Tano‐Menka R, Senjobe F, Gaiha GD. The emerging role for CTL epitope specificity in HIV cure efforts. J Infect Dis. 2021;223(suppl 1):S32‐S37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7883022</ArticleId><ArticleId IdType="pubmed">33586771</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia‐Bates TM, Palma ML, Anderko RR, et al. Dendritic cells focus CTL responses toward highly conserved and topologically important HIV‐1 epitopes. EBioMedicine. 2021;63:103175.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7811131</ArticleId><ArticleId IdType="pubmed">33450518</ArticleId></ArticleIdList></Reference><Reference><Citation>Li F, Finnefrock AC, Dubey SA, et al. Mapping HIV‐1 vaccine induced T‐cell responses: bias towards less‐conserved regions and potential impact on vaccine efficacy in the step study. PLoS One. 2011;6(6):e20479.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3112144</ArticleId><ArticleId IdType="pubmed">21695251</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, McNevin J, Rolland M, et al. Conserved HIV‐1 epitopes continuously elicit subdominant cytotoxic T‐lymphocyte responses. J Infect Dis. 2009;200(12):1825‐1833.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2783836</ArticleId><ArticleId IdType="pubmed">19909083</ArticleId></ArticleIdList></Reference><Reference><Citation>Picker LJ, Lifson JD, Gale M, Hansen SG, Früh K. Programming cytomegalovirus as an HIV vaccine. Trends Immunol. 2023;44(4):287‐304.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10089689</ArticleId><ArticleId IdType="pubmed">36894436</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang P, Narayanan E, Liu Q, et al. A multiclade env–gag VLP mRNA vaccine elicits tier‐2 HIV‐1‐neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques. Nat Med. 2021;27(12):2234‐2245.</Citation><ArticleIdList><ArticleId IdType="pubmed">34887575</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y, Ferguson T, Masuda K, et al. Short carbon nanotube‐based delivery of mRNA for HIV‐1 vaccines. Biomolecules. 2023;13(7):1088.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10377108</ArticleId><ArticleId IdType="pubmed">37509124</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandal S, Ghosh JS, Lohani SC, et al. A long‐term stable cold‐chain‐friendly HIV mRNA vaccine encoding multi‐epitope viral protease cleavage site immunogens inducing immunogen‐specific protective T cell immunity. Emerg Microbes Infect. 2024;13(1):2377606.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11259082</ArticleId><ArticleId IdType="pubmed">38979723</ArticleId></ArticleIdList></Reference><Reference><Citation>Denton PW, Garcia JV. Novel humanized murine models for HIV research. Curr HIV/AIDS Rep. 2009;6(1):13‐19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3739285</ArticleId><ArticleId IdType="pubmed">19149992</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatziioannou T, Evans DT. Animal models for HIV/AIDS research. Nat Rev Microbiol. 2012;10(12):852‐867.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4334372</ArticleId><ArticleId IdType="pubmed">23154262</ArticleId></ArticleIdList></Reference><Reference><Citation>Sui Y, Gordon S, Franchini G, Berzofsky JA. Non‐human primate models for HIV/AIDS vaccine development. Curr Protoc Immunol Ed John E Coligan Al. 2013;102:12.14.1‐12.14.30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3920465</ArticleId><ArticleId IdType="pubmed">24510515</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirsch VM, Goldstein S, Hynes NA, et al. Prolonged clinical latency and survival of macaques given a whole inactivated simian immunodeficiency virus vaccine. J Infect Dis. 1994;170(1):51‐59.</Citation><ArticleIdList><ArticleId IdType="pubmed">8014520</ArticleId></ArticleIdList></Reference><Reference><Citation>Nath BM, Schumann KE, Boyer JD. The chimpanzee and other non‐human‐primate models in HIV‐1 vaccine research. TIM. 2000;8(9):426‐431.</Citation><ArticleIdList><ArticleId IdType="pubmed">10989311</ArticleId></ArticleIdList></Reference><Reference><Citation>Krakoff E, Gagne RB, VandeWoude S, Carver S. Variation in intra‐individual lentiviral evolution rates: a systematic review of human, nonhuman primate, and felid species. J Virol. 2019;93(16):e00538‐19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6675878</ArticleId><ArticleId IdType="pubmed">31167917</ArticleId></ArticleIdList></Reference><Reference><Citation>Wertheim JO, Worobey M. Dating the age of the SIV lineages that gave rise to HIV‐1 and HIV‐2. PLoS Comput Biol. 2009;5(5):e1000377.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2669881</ArticleId><ArticleId IdType="pubmed">19412344</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell SM, Bedford T. Modern‐day SIV viral diversity generated by extensive recombination and cross‐species transmission. PLoS Pathog. 2017;13(7):e1006466.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5510905</ArticleId><ArticleId IdType="pubmed">28672035</ArticleId></ArticleIdList></Reference><Reference><Citation>Policicchio BB, Pandrea I, Apetrei C. Animal models for HIV cure research. Front Immunol. 2016;7:12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4729870</ArticleId><ArticleId IdType="pubmed">26858716</ArticleId></ArticleIdList></Reference><Reference><Citation>Gillgrass A, Wessels JM, Yang JX, Kaushic C. Advances in humanized mouse models to improve understanding of HIV‐1 pathogenesis and immune responses. Front Immunol. 2020;11:617516.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7973037</ArticleId><ArticleId IdType="pubmed">33746940</ArticleId></ArticleIdList></Reference><Reference><Citation>Abeynaike S, Paust S. Humanized mice for the evaluation of novel HIV‐1 therapies. Front Immunol. 2021;12:636775.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8047330</ArticleId><ArticleId IdType="pubmed">33868262</ArticleId></ArticleIdList></Reference><Reference><Citation>Guenter D, Esparza J, Macklin R. Ethical considerations in international HIV vaccine trials: summary of a consultative process conducted by the Joint United Nations Programme on HIV/AIDS (UNAIDS). J Med Ethics. 2000;26(1):37‐43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1733173</ArticleId><ArticleId IdType="pubmed">10701170</ArticleId></ArticleIdList></Reference><Reference><Citation>New guidance on ethical HIV prevention trials published. 2021. Accessed December 27, 2023. 2021. Accessed December 27, 2023. https://www.who.int/news/item/27-01-2021-new-guidance-on-ethical-hiv-prevention-trials-published
</Citation></Reference><Reference><Citation>The Development of HIV Vaccines. December 27, 2023. https://historyofvaccines.org/vaccines-101/future-immunization/development-hiv-vaccines
</Citation></Reference><Reference><Citation>Verywell Health. 2022. Accessed December 27, 2023. Why is it so hard to make an hiv vaccine? 2022. Accessed December 27, 2023. Why is it so hard to make an hiv vaccine? https://www.verywellhealth.com/hiv-vaccine-development-4057071
</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>